Horizon Discovery Expands OncoSpan Reference Standards to FFPE and Liquid Biopsy
Complete the form below to unlock access to ALL audio articles.
Horizon Discovery Group, a company specializing in the application of gene editing and gene modulation for cell line engineering, has announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.
Horizon’s OncoSpan range now includes formalin-fixed, paraffin-embedded (FFPE) and cell-free DNA (cfDNA) formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its well-established genomic DNA (gDNA) format. Its cfDNA format offers a large number of variants and genes, over 380 and 152 respectively, to help standardize liquid biopsy testing.
These cell-line derived reference standards closely mimic patient samples and are intended to offer an unlimited and reproducible resource to help ensure consistency during the establishment and validation of diagnostic assays. All three formats are delivered with batch-specific, next-generation sequencing (NGS) data, orthogonally validated by ddPCR, to allow researchers to further validate their analysis pipeline.
